A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment
DeciBio delivered an in-depth semi-quantitative biomarker testing and treatment landscape analysis (e.g., landscape today, key trends, and expected future growth).
Quantitative and qualitative assessment included:
DeciBio's analysis revealed that the risk of patient attrition from the client's treatment pathway was lower than expected, and DeciBio developed specific tactics the client could implement to mitigate the attrition of those patients who were at risk.
U.S. and EU
Pharma & Biotech
Biomarker and Diagnostic Strategy